Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypofractionated Radiotherapy + GM-CSF + Pomalidomide + Glofitamab in Newly Diagnosed PCNSL
NCT07749365Phase 2Recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Jul 2026
- Primary completion
- Dec 2029
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of glofitamab in primary central nervous system lymphoma (PCNSL), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoint: Complete Response Rate at 12 months. Started Jul 2026; status: recruiting.
02
Drugs
glofitamab
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT07749365.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07749365.